[Teriparatide:benefit and safety for bone disease in CKD patients undergoing hemodialysis]

Clin Calcium. 2016 Sep;26(9):1301-7.
[Article in Japanese]

Abstract

Teriparatide, 1-34 parathyroid hormone, is one of effective treatments for osteoporosis. Teriparatide shows an anabolic effect for bone formation, as a result, increases bone mineral density as well as prevention of fractures in the general population. On the other hand, there are a few report about the effect of teriparatide on increase of bone mineral density in maintenance hemodialysis patients. In addition to CKD-MBD, osteoporosis is also an important pathological change in ESRD patients, therefore its safety and efficacy should be discussed in more detail.

MeSH terms

  • Bone Density / drug effects
  • Bone Density Conservation Agents / administration & dosage
  • Bone Density Conservation Agents / therapeutic use*
  • Bone Diseases / drug therapy*
  • Bone Diseases / etiology
  • Humans
  • Parathyroid Hormone / blood
  • Renal Dialysis
  • Renal Insufficiency, Chronic / complications*
  • Teriparatide / adverse effects
  • Teriparatide / therapeutic use*

Substances

  • Bone Density Conservation Agents
  • Parathyroid Hormone
  • Teriparatide